Method for making heteromultimeric molecules
Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.
1. A method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a bispecific antibody that specifically binds VEGF and DLL4, wherein the bispecific antibody comprises a first and a second immunoglobulin heavy chain polypeptide and a first and a second immunoglobulin light chain polypeptide, wherein the first and second immunoglobulin heavy chain polypeptides each comprises a CH3 domain and the CH3 domains comprise substitutions that promote heterodimerization of the first and second immunoglobulin heavy chain polypeptides, and wherein the first and second light chain polypeptides are identical in amino acid sequence, and wherein the CH3 domains are selected from the group consisting of:
(a) human IgG1 CH3 domains, wherein the substitutions consist of: a glutamate or aspartate at positions in the first immunoglobulin heavy chain polypeptide corresponding to positions 253 and 292 of SEQ ID NO:33, and a lysine at positions in the second immunoglobulin heavy chain polypeptide corresponding to positions 240 and 282 of SEQ ID NO:33;
(b) human IgG2 CH3 domains, wherein the substitutions consist of: a glutamate or aspartate at positions in the first immunoglobulin heavy chain polypeptide corresponding to positions 249 and 288 of SEQ ID NO:34 and a lysine at positions in the second immunoglobulin heavy chain polypeptide corresponding to positions 236 and 278 of SEQ ID NO:34;
(c) human IgG3 CH3 domains, wherein the substitutions consist of: a glutamate or aspartate at positions in the first immunoglobulin heavy chain polypeptide corresponding to positions 300 and 339 of SEQ ID NO:35, and a lysine at positions in the second immunoglobulin heavy chain polypeptide corresponding to 287 and 329 of SEQ ID NO:35; and
(d) human IgG4 CH3 domains, wherein the substitutions consist of: a glutamate or aspartate at positions in the first immunoglobulin heavy chain polypeptide corresponding to positions 250 and 289 of SEQ ID NO:36, and a lysine at positions in the second immunoglobulin heavy chain polypeptide corresponding to positions 237 and 279 of SEQ ID NO:36.
2. The method of claim 1 , wherein the CH3 domains are human IgG2 CH3 domains and the CH3 domain of the first immunoglobulin heavy chain polypeptide comprises SEQ ID NO:5 or SEQ ID NO:7, and the CH3 domain of the second immunoglobulin heavy chain polypeptide comprises SEQ ID NO:9.
3. The method of claim 1 , wherein the CH3 domains are human IgG2 CH3 domains, and wherein the substitutions consist of: a glutamate or aspartate at positions in the first immunoglobulin heavy chain polypeptide corresponding to positions 249 and 288 of SEQ ID NO:34, and a lysine at positions in the second immunoglobulin heavy chain polypeptide corresponding to positions 236 and 278 of SEQ ID NO:34.
4. The method of claim 1 , wherein the bispecific antibody comprises a VEGF binding sequence which comprises a heavy chain variable region of SEQ ID NO:10 and a light chain variable region of SEQ ID NO:31 or SEQ ID NO:32.
5. The method of claim 4 , wherein the VEGF binding sequence comprises a heavy chain of SEQ ID NO:11 and a light chain of SEQ ID NO:13 or SEQ ID NO:15.
6. The method of claim 1 , wherein the bispecific antibody comprises the heavy chain CDR1, CDR2 and CDR3 amino acid sequences and the light chain CDR1, CDR2 and CDR3 amino acid sequences that are contained in the 21M18 antibody produced by the hybridoma with ATCC designation PTA-8670.
7. The method of claim 4 , wherein the bispecific antibody comprises the heavy chain CDR1, CDR2and CDR3amino acid sequences and the light chain CDR1, CDR2and CDR3amino acid sequences that are contained in the 21M18 antibody produced by the hybridoma with ATCC designation PTA-8670.
8. The method of claim 1 , wherein each immunoglobulin heavy chain polypeptide is linked to the immunoglobulin light chain polypeptide.
9. The method of claim 1 , wherein the bispecific antibody further comprises a cytotoxin or a radioisotope.
10. The method of claim 1 , wherein the cancer is selected from the group consisting of: ovarian cancer, lung cancer, pancreatic cancer, breast cancer, colon cancer, colorectal cancer, hepatocellular cancer, gastrointestinal cancer, glioblastoma, cervical cancer, bladder cancer, endometrial or uterine carcinoma, kidney cancer, liver cancer, prostate cancer, and various types of head and neck cancer.
11. The method of claim 1 , further comprising administering a second therapeutic agent.
12. The method of claim 11 , wherein the bispecific antibody and the second therapeutic agent are administered in any order.
13. The method of claim 11 , wherein the bispecific antibody and the second therapeutic agent are administered simultaneously.
14. The method of claim 11 , wherein the second therapeutic agent is an anti-cancer agent.
15. The method of claim 11 , wherein the second therapeutic agent is at least one chemotherapeutic agent.
16. The method of claim 11 , wherein the second therapeutic agent is an antibody against a tumor-associated antigen.
17. The method of claim 1 , wherein the treatment further comprises radiation therapy.
18. A method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a bispecific antibody that specifically binds VEGF and DLL4, wherein the bispecific antibody comprises a first and a second immunoglobulin heavy chain polypeptide and a first and a second immunoglobulin light chain polypeptide, wherein the first and second immunoglobulin heavy chain polypeptides each comprises a CH3 domain and the CH3 domains comprise substitutions that promote heterodimerization of the first and second immunoglobulin heavy chain polypeptides, wherein the CH3 domain is a human IgG2 CH3 domain, and wherein the substitutions consist of: a glutamate or aspartate at positions in the first immunoglobulin heavy chain polypeptide corresponding to positions 249 and 288 of SEQ ID NO:34, and a lysine at positions in the second immunoglobulin heavy chain polypeptide corresponding to positions 236 and 278 of SEQ ID NO:34, and wherein the bispecific antibody comprises the heavy chain CDR1, CDR2 and CDR3 amino acid sequences and the light chain CDR1, CDR2 and CDR3 amino acid sequences that are contained in the 21M18 antibody produced by the hybridoma with ATCC designation PTA-8670.